Genexine Raises New Funds To Progress Promising HPV, Other Projects
This article was originally published in PharmAsia News
South Korean bioventure Genexine is on track to meet its goal of progressing and expanding this year the clinical development of its leading assets - orphan disease drugs and cancer immunotherapies. The company now plans to raise new funds via share and bond issues to domestic and overseas investors including its Chinese strategic alliance partner Tasly.
Register for our free email digests: